Press coverage about Amphastar Pharmaceuticals (NASDAQ:AMPH) has trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amphastar Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.8094258110098 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Amphastar Pharmaceuticals : to Present at the 29th Annual Piper Jaffray Healthcare Conference (4-traders.com)
- Sanofi Wins Fees After Ditching ‘Clearly Frivolous’ FCA Suit (law360.com)
- Amphastar Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference – EconoTimes (econotimes.com)
- Insider Selling: Amphastar Pharmaceuticals, Inc. (AMPH) Director Sells 7,862 Shares of Stock (americanbankingnews.com)
Amphastar Pharmaceuticals (NASDAQ:AMPH) opened at $18.90 on Thursday. The company has a market cap of $868.02, a PE ratio of 125.87 and a beta of 1.68. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.86 and a current ratio of 3.08. Amphastar Pharmaceuticals has a one year low of $12.05 and a one year high of $21.75.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Wednesday, November 8th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.05. Amphastar Pharmaceuticals had a net margin of 0.12% and a return on equity of 2.30%. The company had revenue of $57.90 million during the quarter, compared to the consensus estimate of $57.23 million. During the same period in the prior year, the firm earned $0.14 earnings per share. Amphastar Pharmaceuticals’s revenue was down 9.8% on a year-over-year basis. sell-side analysts predict that Amphastar Pharmaceuticals will post -0.03 EPS for the current year.
Amphastar Pharmaceuticals declared that its board has initiated a share buyback program on Wednesday, August 9th that authorizes the company to repurchase $20.00 million in shares. This repurchase authorization authorizes the company to repurchase up to 2.8% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s board of directors believes its shares are undervalued.
Several equities analysts have recently commented on the stock. Piper Jaffray Companies reaffirmed a “buy” rating and set a $19.00 price objective on shares of Amphastar Pharmaceuticals in a research note on Sunday, September 17th. BMO Capital Markets reaffirmed a “hold” rating and set a $16.00 price objective on shares of Amphastar Pharmaceuticals in a research note on Monday, July 31st. Jefferies Group LLC reaffirmed a “buy” rating and set a $19.00 price objective (down from $20.00) on shares of Amphastar Pharmaceuticals in a research note on Friday, August 11th. BidaskClub downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, July 28th. Finally, Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $20.43.
ILLEGAL ACTIVITY NOTICE: This news story was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://sportsperspectives.com/2017/11/23/amphastar-pharmaceuticals-amph-earning-somewhat-positive-media-coverage-study-shows.html.
In related news, CFO William J. Peters sold 3,026 shares of the stock in a transaction dated Friday, October 13th. The shares were sold at an average price of $18.56, for a total value of $56,162.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Stephen B. Shohet sold 7,862 shares of the stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $18.04, for a total transaction of $141,830.48. Following the completion of the transaction, the director now directly owns 31,978 shares of the company’s stock, valued at $576,883.12. The disclosure for this sale can be found here. Over the last three months, insiders sold 164,193 shares of company stock valued at $3,018,857. 11.10% of the stock is owned by insiders.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.